Home Podcasts CLOT Conversations
CLOT Conversations

CLOT Conversations

Thrombosis Canada 59 episodes Sep 11, 2026

CLOT Conversations is a podcast for healthcare professionals focused on the latest advances in thrombosis diagnosis and management. It is hosted by Dr Jameel Abdulrehman, a hematologist specializing in thrombosis and hemostasis at the University Health Network in Toronto, and David Airdrie, executive director of Thrombosis Canada. In short, digestible episodes, they discuss new research and the evolving field of thrombosis. The show is produced by Thrombosis Canada and points listeners to the organization's resources, tools, and programs for improving patient care and outcomes.

Episodes

OCEANIC-STROKE: Rethinking Secondary Stroke Prevention with Dr. Mike Sharma
OCEANIC-STROKE: Rethinking Secondary Stroke Prevention with Dr. Mike Sharma Sep 11, 2026 24:06 Send us Fan MailFor decades, antiplatelet therapy has been central to secondary prevention following noncardioembolic ischemic stroke. Could factor XIa inhibition offer another approach?Dr. Mike Sharma, principal investigator and first author of OCEANIC-STROKE, joins Dr. Maha Othman and Dr. Jameel Abdulrehman to discuss the phase 3 trial of asundexian for secondary stroke prevention.OCEANIC-STROKE
Acute PE: New Categories, Faster Decisions and What Changes in Practice
Acute PE: New Categories, Faster Decisions and What Changes in Practice Aug 26, 2026 32:39 Send us Fan MailDr. Lana Castellucci and Dr. Kerstin de Wit join CLOT Conversations to discuss the 2026 guideline for the evaluation and management of acute pulmonary embolism in adults and what its recommendations mean for clinical practice.The conversation explores the new A–E clinical categories for acute PE, including how to recognize patients whose condition may be deteriorating despite not m
EPCAT III: Is Aspirin Alone Enough After Hip or Knee Arthroplasty?
EPCAT III: Is Aspirin Alone Enough After Hip or Knee Arthroplasty? Aug 11, 2026 19:13 Send us Fan MailIs aspirin alone enough to prevent venous thromboembolism after total hip or knee arthroplasty?In this episode of CLOT Conversations, Dr. Jameel Abdulrehman speaks with Dr. Sudeep Shivakumar, lead author of the EPCAT III trial, recently published in the New England Journal of Medicine.EPCAT III randomized more than 5,400 patients undergoing hip or knee arthroplasty to receive aspir
Hormones, Clots, and Clinical Decisions with Dr Shannon Bates and Dr Leslie Skeith
Hormones, Clots, and Clinical Decisions with Dr Shannon Bates and Dr Leslie Skeith Jun 17, 2026 31:40 Send us Fan MailHormone therapy is used across a wide range of clinical settings—from contraception and menopause management to pregnancy care and gender-affirming therapy. But how do these treatments influence thrombosis risk, and how should clinicians approach these decisions in practice?In this episode of CLOT Conversations, hosts Dr. Jameel Abdulrehman and Dr. Maha Othman speak with Dr. Leslie
C-TRACT Trial: Endovascular Therapy for Post-Thrombotic Syndrome with Dr. Susan Kahn
C-TRACT Trial: Endovascular Therapy for Post-Thrombotic Syndrome with Dr. Susan Kahn Jun 4, 2026 23:26 Send us Fan MailPost-thrombotic syndrome (PTS) affects up to half of patients following deep vein thrombosis and can significantly impair quality of life. Yet treatment options have historically been limited.In this episode of CLOT Conversations, David Airdrie and Dr. Jameel Abdulrehman speak with Dr. Susan Kahn about the recently published C-TRACT trial in The New England Journal of Medicine.The
Surgical and Procedural Bleed Risk Stratification in Anticoagulated Patients: ISTH Guidance in Practice
Surgical and Procedural Bleed Risk Stratification in Anticoagulated Patients: ISTH Guidance in Practice Apr 29, 2026 29:45 Send us Fan MailPerioperative anticoagulation management is a common and complex clinical challenge. In this episode of CLOT Conversations, Drs. James Douketis and Joseph Shaw discuss new ISTH guidance on surgical and procedural bleed risk stratification in anticoagulated patients.The discussion explores why updated guidance was needed, addressing inconsistencies in prior schemas, and introduces a
Which DOAC Bleeds Less? COBRRA Trial Insights for VTE Care with Dr Lana Castellucci
Which DOAC Bleeds Less? COBRRA Trial Insights for VTE Care with Dr Lana Castellucci Apr 6, 2026 16:24 Send us Fan MailWhich DOAC bleeds less in acute VTE?In this episode, we explore the COBRRA trial comparing apixaban vs rivaroxaban and what it means for clinical practice.The COBRRA trial provides the first direct, randomized comparison of apixaban and rivaroxaban for the treatment of acute venous thromboembolism (VTE).In this episode of CLOT Conversations, Dr. Lana Castellucci discusses findings
ARTESiA: Apixaban vs Aspirin Bleeding Risk with Dr D Siegal
ARTESiA: Apixaban vs Aspirin Bleeding Risk with Dr D Siegal Feb 18, 2026 17:37 Send us Fan MailMajor bleeding remains the principal complication of oral anticoagulation. In patients with device-detected subclinical atrial fibrillation, the decision to anticoagulate requires careful balancing of stroke prevention against bleeding risk.In this episode of CLOT Conversations, Dr. Deborah Siegal discusses a prespecified subanalysis of the ARTESiA randomized clinical trial, recent
WAVe Study: Cancer, Obesity, Anticoagulation with Dr Tzu-Fei Wang and Dr Gregoire Le Gal
WAVe Study: Cancer, Obesity, Anticoagulation with Dr Tzu-Fei Wang and Dr Gregoire Le Gal Dec 16, 2025 21:56 Send us Fan MailObesity presents a persistent challenge in the management of cancer-associated thrombosis, particularly when prescribing low molecular weight heparin beyond standard dose caps.In this episode of CLOT Conversations, host Dr. Jameel Abdulrehman is joined by Dr. Tzu-Fei Wang and Dr. Grégoire Le Gal to discuss findings from the WAVe study, a multicenter prospective cohort study evaluat
ROXI-VTE Trials Explained: Dr. Jeff Weitz on Next-Generation Thrombosis Prevention
ROXI-VTE Trials Explained: Dr. Jeff Weitz on Next-Generation Thrombosis Prevention Dec 3, 2025 22:29 Send us Fan MailIn this episode of CLOT Conversations, co-hosts Dr. Jamil Abdul-Rahman and Dr. Maha Othman have an in-depth discussion with leading thrombosis expert Dr. Jeff Weitz. Together, they unpack new findings from The Lancet on RGN-9933 and RGN-7508, two investigational factor XI inhibitors evaluated in the ROXI-VTE I and II phase-2 trials. These studies examine how targeted inhibition of
Diagnosing the “Second Clot”: Lessons from PREDICTORS with Dr Vicky Mai and Dr Grégoire Le Gal
Diagnosing the “Second Clot”: Lessons from PREDICTORS with Dr Vicky Mai and Dr Grégoire Le Gal Oct 3, 2025 17:26 Send us Fan MailDiagnosing recurrent venous thromboembolism (VTE) remains one of the biggest clinical challenges in thrombosis medicine. In this episode, Dr. Vicky Mai and Dr. Grégoire Le Gal join us to discuss the international PREDICTORS study (JTH, 2025), which evaluated the performance of commonly used clinical decision rules (Wells and Geneva scores) in patients with suspected recurrent VTE.
Low Health Literacy in Pediatric Thrombosis: Clinical Risks and Realities - L. Avila and J. Vincelli
Low Health Literacy in Pediatric Thrombosis: Clinical Risks and Realities - L. Avila and J. Vincelli Sep 5, 2025 15:37 Send us Fan MailThis episode reviews findings from a cross-sectional study at SickKids on health literacy in pediatric VTE patients and caregivers (Res Pract Thromb Haemost, 2025). Among 101 participants, 74% of adolescents and 59% of parents/caregivers demonstrated low general health literacy using REALM, HAS-A, and eHEALS instruments. Communication with providers was the most affected domain, an

Recommended